How to Switch from Enoxaparin (Lovenox) to Apixaban
Stop enoxaparin and start apixaban at the time of the next scheduled enoxaparin dose—no bridging or overlap is required. This direct transition is safe and effective based on FDA-approved dosing protocols and guideline recommendations 1.
Practical Switching Protocol
Timing of the Switch
- Discontinue enoxaparin at its last scheduled dose
- Begin apixaban at the time when the next enoxaparin dose would have been due
- No overlap period is necessary between the two medications 1
Apixaban Dosing After Switch
The dose depends on the indication and treatment phase:
For VTE Treatment (DVT/PE):
For Extended VTE Prevention (after ≥6 months of treatment):
For Post-Surgical VTE Prophylaxis:
- Apixaban 2.5 mg orally twice daily 1
Key Advantages of This Approach
Unlike switching to dabigatran or edoxaban (which require 5-10 days of parenteral anticoagulation first), apixaban can be started immediately without any lead-in parenteral therapy 3. This is a critical distinction that simplifies the transition process.
Pharmacodynamic Considerations
Research demonstrates that when switching from enoxaparin to apixaban:
- Enoxaparin does not affect apixaban pharmacokinetics 4
- Anti-Xa activity increases are additive but modest when medications overlap 4
- Separating administration by 12 hours (i.e., starting apixaban at the next scheduled enoxaparin dose) minimizes any pharmacodynamic interaction 4
Special Populations
Cancer Patients: While LMWH (including enoxaparin) remains preferred for cancer-associated thrombosis in the first 3 months 5, 3, apixaban can be used when LMWH is not feasible. The 2022 ITAC guidelines note that apixaban (along with other DOACs) can be used for initial VTE treatment in cancer patients without high gastrointestinal or genitourinary bleeding risk 5.
Renal Impairment: Ensure creatinine clearance is ≥30 mL/min before switching to apixaban, as it is contraindicated below this threshold 5, 3.
Drug Interactions: If the patient is on combined P-glycoprotein and strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir), reduce the apixaban dose by 50% 1.
Common Pitfalls to Avoid
- Do NOT bridge with both medications simultaneously for extended periods—this increases bleeding risk without benefit
- Do NOT use the atrial fibrillation dose (5 mg twice daily) when treating VTE; the initial VTE dose is 10 mg twice daily for 7 days 2
- Do NOT delay the switch unnecessarily—apixaban reaches therapeutic levels quickly and does not require parenteral overlap like warfarin does
- Do NOT forget to counsel patients that apixaban is taken twice daily (unlike once-daily rivaroxaban or edoxaban)
Patient Counseling Points
- Take apixaban with or without food (unlike rivaroxaban which requires food)
- If a dose is missed, take it as soon as remembered on the same day—do not double the next dose 1
- Apixaban offers superior convenience compared to subcutaneous enoxaparin, with comparable or better safety profiles in recent studies 6, 7, 8, 9, 10